In contrast, a Phase I study in patients with biochemically recurrent prostate cancer treated with Epidiolex (CBD, Clinical trial NCT04428203) demonstrated good tolerability at doses up to 800 mg/day, with most patients exhibiting biochemical disease stability and a subset of patients showing partial reductions in prostate-specific antigen (PSA) levels. Here, KLK3 is linked to prostate cancer.